Papers/PMID:35282455
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Frontiers in endocrinology2022The record
3 findings · 1 compound · 3 endpoints · 2 null
What it reported
How to read these marksWhat moved
1 finding
empagliflozin — decreases aspartate aminotransferase
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Meta-analysis concluded that empagliflozin was able to decrease AST levels among patients suffering from NAFLD compared with controls; the statistical difference was significant (MD: −3.10, 95% CI: −6.18 to −0.02, p = 0.05, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Effect -3.1 mean difference, 95% CI -6.18 to -0.02
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
What did not
2 findings
empagliflozin — no detected effect on fasting blood glucose
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“In comparison with the control group, empagliflozin treatment can attenuate HOMA-IR levels, the statistical difference was significant (MD: −0.45, 95% CI: −0.90 to 0.00, p = 0.05, I2 = 0%), but there were no significant diversity in HbA1c (MD: −0.10, 95% CI: −0.60 to −0.40, p = 0.70, I2 = 42.79%), FBS (MD: −1.21, 95% CI: −4.98 to 2.55, p = 0.53, I2 = 0%), insulin (MD: 3.63, 95% CI: −7.64 to 14.90, p = 0.53, I2 = 90%), and HOMA2-IR (MD: −0.12, 95% CI: −0.45 to 0.20, p = 0.46, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Effect -1.21 mean difference, 95% CI -4.98 to 2.55
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
empagliflozin — no detected effect on glycated haemoglobin (HbA1c)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1“In comparison with the control group, empagliflozin treatment can attenuate HOMA-IR levels, the statistical difference was significant (MD: −0.45, 95% CI: −0.90 to 0.00, p = 0.05, I2 = 0%), but there were no significant diversity in HbA1c (MD: −0.10, 95% CI: −0.60 to −0.40, p = 0.70, I2 = 42.79%), FBS (MD: −1.21, 95% CI: −4.98 to 2.55, p = 0.53, I2 = 0%), insulin (MD: 3.63, 95% CI: −7.64 to 14.90, p = 0.53, I2 = 90%), and HOMA2-IR (MD: −0.12, 95% CI: −0.45 to 0.20, p = 0.46, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink